𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort

✍ Scribed by Anna S. F. Lok; Marc G. Ghany; Zachary D. Goodman; Elizabeth C. Wright; Gregory T. Everson; Richard K. Sterling; James E. Everhart; Karen L. Lindsay; Herbert L. Bonkovsky; Adrian M. Di Bisceglie; William M. Lee; Timothy R. Morgan; Jules L. Dienstag; Chihiro Morishima


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
150 KB
Volume
42
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Knowledge of the presence of cirrhosis is important for the management of patients with chronic hepatitis C (CHC). Most models for predicting cirrhosis were derived from small numbers of patients and included subjective variables or laboratory tests that are not readily available. The aim of this study was to develop a predictive model of cirrhosis in patients with CHC based on standard laboratory tests. Data from 1,141 CHC patients including 429 with cirrhosis were analyzed. All biopsies were read by a panel of pathologists (blinded to clinical features), and fibrosis stage was determined by consensus. The cohort was divided into a training set (n = 783) and a validation set (n = 358). Variables that were significantly different between patients with and without cirrhosis in univariate analysis were entered into logistic regression models, and the performance of each model was compared. The area under the receiver-operating characteristic curve of the final model comprising platelet count, AST/ALT ratio, and INR in the training and validation sets was 0.78 and 0.81, respectively. A cutoff of less than 0.2 to exclude cirrhosis would misclassify only 7.8% of patients with cirrhosis, while a cutoff of greater than 0.5 to confirm cirrhosis would misclassify 14.8% of patients without cirrhosis. The model performed equally well in fragmented and nonfragmented biopsies and in biopsies of varying lengths. Use of this model might obviate the requirement for a liver biopsy in 50% of patients with CHC. In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC.


πŸ“œ SIMILAR VOLUMES


Evolution of hepatic steatosis in patien
✍ Anna S. Lok; James E. Everhart; Raymond T. Chung; Hae-Young Kim; Gregory T. Ever πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 404 KB πŸ‘ 1 views

Hepatic steatosis is a common histologic feature in patients with chronic hepatitis C (CHC) but there are no large longitudinal studies describing the progression of steatosis in CHC. We examined changes in steatosis on serial biopsies among CHC patients participating in the Hepatitis C Antiviral Lo

Final results of a double-blind, placebo
✍ Paul J. Pockros; Lennox Jeffers; Nezam Afdhal; Zachary D. Goodman; David Nelson; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 383 KB πŸ‘ 1 views

## Interferon-β₯1b (IFN-β₯1b ) is a pleiotropic cytokine that displays antifibrotic, antiviral, and antiproliferative activity. A total of 502 patients with compensated liver disease and an Ishak fibrosis score of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these pati

Serum insulin-like growth factor I evalu
✍ Gherardo Mazziotti; Francesca Sorvillo; Filomena Morisco; Antonella Carbone; Mar πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 108 KB πŸ‘ 3 views

## Background: Although experimental studies have demonstrated an important role of insulin-like growth factor i (igf-i) in hepatocarcinogenesis, the clinical data about igf-i in patients with hepatocellular carcinoma (hcc) are scarce and controversial. to the authors' knowledge, this is the first

IL28B alleles associated with poor hepat
✍ Pierre-Yves Bochud; StΓ©phanie Bibert; ZoltΓ‘n Kutalik; Etienne Patin; Julien Guer πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 375 KB πŸ‘ 1 views

Poynard owns stock in Biopredictive. He also consults for and is on the speakers' bureau of Merck. Dr. Pol consults for, advises, and is on the speakers' bureau of Boehringer Ingleheim, Abbott, and GlaxoSmithKline. He consults for, advises, is on the speakers' bureau of, and received grants from Roc